Pasar al contenido principal

MOLECULAS PARA EL TRATAMIENTO DE ENFERMEDADES COMPLEJAS ASOCIADAS A LA EDAD

SAF2015-65586-R

•
Nombre agencia financiadora Ministerio de Economía y Competitividad
Acrónimo agencia financiadora MINECO
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2015
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Unidad de gestión Dirección General de Investigación Científica y Técnica
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)
Identificador persistente http://dx.doi.org/10.13039/501100003329

Resultados relacionados

Resultados totales (Incluyendo duplicados): 33
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Multitarget-Directed Ligands Combining Cholinesterase and Monoamine Oxidase Inhibition with Histamine H3R Antagonism for Neurodegenerative Diseases

  • Bautista-Aguilera, Óscar M.
  • Hagenow, S.
  • Palomino-Antolín, Alejandra
  • Farré-Alins, V.
  • Ismaili, L.
  • Joffrin, P. L.
  • Jimeno, M. Luisa
  • Soukup, Ondrej
  • Janockova, Jana
  • Kalinowski, A.
  • Proschak, E.
  • Iriepa, Isabel
  • Moraleda, I.
  • Schwed, J. S.
  • Romero Jódar, Alejandro
  • López-Muñoz, Francisco
  • Chioua, Mourad
  • Egea, Javier
  • Ramsay, R. R.
  • Marco-Contelles, José
  • Stark, H.
The therapy of complex neurodegenerative diseases requires the development of multitarget-directed drugs (MTDs). Novel indole derivatives with inhibitory activity towards acetyl/butyrylcholinesterases and monoamine oxidases A/B as well as the histamine H receptor (H3R) were obtained by optimization of the neuroprotectant ASS234 by incorporating generally accepted H3R pharmacophore motifs. These small-molecule hits demonstrated balanced activities at the targets, mostly in the nanomolar concentration range. Additional in vitro studies showed antioxidative neuroprotective effects as well as the ability to penetrate the blood–brain barrier. With this promising in vitro profile, contilisant (at 1 mg kg i.p.) also significantly improved lipopolysaccharide-induced cognitive deficits., J.M.C. thanks MINECO (SAF2012-33304 and SAF2015- 65586-R). J.M.C., F.L.M., and A.R. thank UCJC for grants 2015-12, 2014-35, and 2015-21, respectively. J.E. thanks the Fondo de Investigaciones Sanitarias (FIS) (ISCIII/FEDER) (Programa Miguel Servet: CP14/00008 and PI16/00735) and Fundación Mutua Madrileña. O.S. and J.J. thank MHCZDRO (UHHK 00179906) for support. R.R.R., H.S., and J.M.C. acknowledge the EU COST Actions CM1103 and CM15135. E.P. and H.S. thank the German Research Foundation (DFG; PRO 1405/2-2, PRO 1405/4-1, SFB 1039 A07, and INST208/664-1)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Neuroinflammation Signaling Modulated by ASS234, a Multitarget Small Molecule for Alzheimer's Disease Therapy

  • Pino, Javier del
  • Marco-Contelles, José
  • López-Muñoz, Francisco
  • Romero Jódar, Alejandro
  • Ramos, Eva
There is clear evidence that neuroinflammation plays a crucial role in the pathogenesis of Alzheimer's disease. Consequently, modulating the inflammatory environment in brain has become a powerful and attractive strategy to deal with Alzheimer's disease physiopathology. In spite of the neuroprotective capacity shown by ASS234, a multitarget propargylamine targeted for Alzheimer's disease, its regulation of inflammation in the brain still remains unexplored. Therefore, we aimed to characterize possible anti-inflammatory effects of ASS234, counteracting induced inflammatory effects in RAW 264.7 cells and evaluating seven neuroinflammation related genes expression profiling (IL-6, IL-10, IL1β, NF-κB, TNF-α, TNFR1, and TGF-β), after ASS234 (5 μM) treatment in SH-SY5Y cells. The analysis of the obtained fold changes lead us to conclude that ASS234 may play an important role facing the neuroinflammatory environment in Alzheimer's disease pathology., J.M.-C. is indebted to MINECO for Grants SAF2012-33304 and SAF2015-65586-R. The authors thank Camilo José Cela University [Project 2015-21 (HISCHEMAO)] for its continued support., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

In silico assessment of the metabolism and its safety significance of multitarget propargylamine ASS234

  • Ramos, Eva
  • Marco-Contelles, José
  • López-Muñoz, Francisco
  • Romero Jódar, Alejandro
descripción no proporcionada por scopus, JMC is indebted to MINECO for grants SAF2012-33304, and SAF2015-65586-R. The authors thank Camilo José Cela University [Project 2015-21 (HISCHEMAO)] for its continued support., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Facts, Results, and Perspectives of the Current Alzheimer's Disease Research

  • Marco-Contelles, José
Credit should be granted to medicinal chemists with a solid background in organic chemistry and computational chemistry, able to read, understand, and discuss the biological data, in order to design new and more efficient therapeutic approaches for Alzheimer's disease., J.M.-C. thanks MINECO (Government of Spain) (SAF2015- 65586-R) and Universidad Camilo José Cela (NitroStroke project, 2015-12) for support, Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Contilisant, a Tetratarget Small Molecule for Alzheimer's Disease Therapy Combining Cholinesterase, Monoamine Oxidase Inhibition, and H3R Antagonism with S1R Agonism Profile

  • Bautista-Aguilera, Óscar M.
  • Budni, J.
  • Mina, F.
  • Medeiros, E. B.
  • Deuther-Conrad, W.
  • Entrena, J. M.
  • Moraleda, I.
  • Iriepa, Isabel
  • López-Muñoz, Francisco
  • Marco-Contelles, José
Contilisant, a permeable, antioxidant, and neuroprotectant agent, showing high nM affinity at H3R and excellent inhibition of the monoamine oxidases and cholinesterases, is an affine and selective S1R agonist in the nanomolar range, based on the binding affinity and functional experiment, a result confirmed by molecular modeling. In addition, contilisant significantly restores the cognitive deficit induced by Aβ in the radial maze assay in an in vivo Alzheimer's disease test, comparing very favorably with donepezil., J.M.-C. thanks MINECO (Grant SAF2015-65586-R), UCJC (Grants 2015-12, 2014-35, and 2015-21), and EU (COST Action CA15135) for support. J.M.-C. thanks Prof. Stark and Prof. Ramsay, as well as Prof. Jia (Beijing Normal University), Dr. Chioua (CSIC), and Dr. Romero (UCM) for their help and support., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Synthesis and Neuroprotective Properties of N-Substituted C-Dialkoxyphosphorylated Nitrones

  • Piotrowska, Dorota G.
  • Mediavilla, L.
  • Cuarental, L.
  • Głowacka, Iwona E.
  • Marco-Contelles, José
  • Hadjipavlou-Litina, Dimitra
  • López-Muñoz, Francisco
  • Oset-Gasque, María Jesús
Herein, we report the synthesis and neuroprotective power of some N-substituted C-(dialkoxy)phosphorylated nitrones 4a-g, by studying their ability to increase the cell viability, as well as their capacity to reduce necrosis and apoptosis. We have identified (Z)-N-tert-butyl-1-(diethoxyphosphoryl)methanimine oxide (4e) as the most potent, nontoxic, and neuroprotective agent, with a high activity against neuronal necrotic cell death, a result that correlates very well with its great capacity for the inhibition of the superoxide production (72%), as well as with the inhibition of lipid peroxidation (62%), and the 5-lipoxygenase activity (45%) at 100 μM concentrations. Thus, nitrone 4e could be a convenient promising compound for further investigation., The synthetic part of the project was supported by the National Science Centre (grant UMO-2015/17/B/ST5/ 00076). D.H.-L. gratefully acknowledges Dr A. Leo and Biobyte Corp., 201 West 4th Street, Suite 204, Claremont, CA 91711, for free access to the C-QSAR program. J.M.-C. and M.J.O.-G. thank MINECO (Government of Spain) (SAF2015- 65586-R) and Universidad Camilo José Cela (NitroStroke project, 2015-12) for support., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

New Quinolylnitrones for Stroke Therapy: Antioxidant and Neuroprotective (Z)- N- tert-Butyl-1-(2-chloro-6-methoxyquinolin-3-yl)methanimine Oxide as a New Lead-Compound for Ischemic Stroke Treatment

  • Chioua, Mourad
  • Martínez-Alonso, Emma
  • Gonzalo-Gobernado, Rafael
  • Ayuso, María I.
  • Escobar-Peso, Alejandro
  • Infantes, Lourdes
  • Hadjipavlou-Litina, Dimitra
  • Montoya, Juan J.
  • Montaner, Joan
  • Alcázar, Alberto
  • Marco-Contelles, José
We describe herein the synthesis and neuroprotective capacity of an array of 31 compounds comprising quinolyloximes, quinolylhydrazones, quinolylimines, QNs, and related heterocyclic azolylnitrones. Neuronal cultures subjected to oxygen-glucose deprivation (OGD), as experimental model for ischemic conditions, were treated with our molecules at the onset of recovery period after OGD and showed that most of these QNs, but not the azo molecules, improved neuronal viability 24 h after recovery. Especially, QN (Z)-N-tert-butyl-1-(2-chloro-6-methoxyquinolin-3-yl)methanimine oxide (23) was shown as a very potent neuroprotective agent. Antioxidant analysis based on the ability of QN 23 to trap different types of toxic radical oxygenated species supported and confirmed its strong neuroprotective capacity. Finally, QN 23 showed also neuroprotection induction in two in vivo models of cerebral ischemia, decreasing neuronal death and reducing infarct size, allowing us to conclude that QN 23 can be considered as new lead-compound for ischemic stroke treatment., This work was supported by grants from the Spanish Ministry of Economy and Competitiveness (Grants SAF2012-33304 and SAF2015-65586-R) and Universidad Camilo José Cela (NitroStroke 2015-12) to J.M.-C., the Instituto de Salud Carlos III and cofinancing by the European Development Regional Fund (FEDER) (Grants PI14/00705, PI18/0255, and RETICS RD16/0019/0006) to A.A., and the Regional Madrid Government (BIPEDD-2, Grant S2010-BMD-2457) to L.I. We thank Isquaemia Biotech SL for its financial support. A.A. thanks M. Gómez-Calcerrada for technical assistance., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Novel Quinolylnitrones Combining Neuroprotective and Antioxidant Properties

  • Chioua, Mourad
  • Salgado-Ramos, M.
  • Diez-Iriepa, Daniel
  • Escobar-Peso, Alejandro
  • Iriepa, Isabel
  • Hadjipavlou-Litina, Dimitra
  • Martínez-Alonso, Emma
  • Alcázar, Alberto
  • Marco-Contelles, José
We describe here the preparation, neuroprotective analysis, and antioxidant capacity of 11 novel quinolylnitrones (QN). The neuroprotective analysis of QN1-11 in an oxygen-glucose deprivation model, in primary neuronal cultures, has been determined, allowing us to identify QN6 as a very potent neuroprotective agent, showing significant high value at 0.5 and 10 μM (86.2%), a result in good agreement with the observed strong hydroxyl radical scavenger of QN6., This work was supported by grants from the Spanish Ministry of Economy and Competitiveness (SAF2015-65586-R) to J.M.-C., and the Instituto de Salud Carlos III and cofinancing by the European Development Regional Fund (FEDER) (PI14/ 00705, PI18/0255 and RETICS RD16/0019/0006) to A.A. and (IFI18/00011) to A.E.-P., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The APPswe/PS1A246E mutations in an astrocytic cell line leads to increased vulnerability to oxygen and glucose deprivation, Ca2+ dysregulation, and mitochondrial abnormalities

  • Martin-de-Saavedra, María
  • Navarro, Elisa
  • Moreno-Ortega, Ana J.
  • Cunha, Mauricio P.
  • Buendía Abaitua, Izaskun
  • Hernansanz-Agustín, Pablo
  • León, Rafael
  • Cano-Abad, María F.
  • Martínez-Ruiz, Antonio
  • Martínez-Murillo, Ricardo
  • Duchen, Michael R.
  • López, Manuela G.
Growing evidence suggests a close relationship between Alzheimer's Disease (AD) and cerebral hypoxia. Astrocytes play a key role in brain homeostasis and disease states, while some of the earliest changes in AD occur in astrocytes. We have therefore investigated whether mutations associated with AD increase astrocyte vulnerability to ischemia. Two astroglioma cell lines derived from APPSWE /PS1A246E (APP, amyloid precursor protein; PS1, presenilin 1) transgenic mice and controls from normal mice were subjected to oxygen and glucose deprivation (OGD), an in vitro model of ischemia. Cell death was increased in the APPSWE /PS1A246E line compared to the control. Increasing extracellular calcium concentration ([Ca2+ ]) exacerbated cell death in the mutant but not in the control cells. In order to explore cellular Ca2+ homeostasis, the cells were challenged with ATP or thapsigargin and [Ca2+ ] was measured by fluorescence microscopy. Changes in cytosolic Ca2+ concentration ([Ca2+ ]c ) were potentiated in the APPSWE /PS1A246E transgenic line. Mitochondrial function was also altered in the APPSWE /PS1A246E astroglioma cells; mitochondrial membrane potential and production of reactive oxygen species were increased, while mitochondrial basal respiratory rate and ATP production were decreased compared to control astroglioma cells. These results suggest that AD mutations in astrocytes make them more sensitive to ischemia; Ca2+ dysregulation and mitochondrial dysfunction may contribute to this increased vulnerability. Our results also highlight the role of astrocyte dyshomeostasis in the pathophysiology of neurodegenerative brain disorders., This work was supported by the Spanish Government (partially funded by the European Union ERDF/FEDER) Ref. SAF2015-63935R to M.G.L.; Ref. SAF2015-65586 to R.M.M; Ref. PI15/ 00107 to A.M.R.; FPU/contract Ref. AP2009/0343 to A.J.M.O., the Spanish Ministry of Health (Instituto de Salud Carlos III) Ref. PI14/00372 to R.L and a grant from the Fundación Domingo Martínez (Spain) to A.M.R. and M.G.L. R.L. thanks the Instituto de Salud Carlos III and the European Regional Development’s funds (FEDER) for a research contract under the Miguel Servet II Program (CPII16/00014). We also thank the Fundación Teófilo Hernando for its continuous support., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Exploring structure-activity relationship in tacrine-squaramide derivatives as potent cholinesterase inhibitors

  • Svobodova, Barbora
  • Mezeiova, Eva
  • Hepnarova, Vendula
  • Hrabinova, Martina
  • Muckova, Lubica
  • Kobrlova, Tereza
  • Jun, Daniel
  • Soukup, Ondrej
  • Jimeno, M. Luisa
  • Marco-Contelles, José
  • Korábečný, Jan
Tacrine was the first drug to be approved for Alzheimer’s disease (AD) treatment, acting as a cholinesterase inhibitor. The neuropathological hallmarks of AD are amyloid-rich senile plaques, neurofibrillary tangles, and neuronal degeneration. The portfolio of currently approved drugs for AD includes acetylcholinesterase inhibitors (AChEIs) and N-methyl-d-aspartate (NMDA) receptor antagonist. Squaric acid is a versatile structural scaffold capable to be easily transformed into amide-bearing compounds that feature both hydrogen bond donor and acceptor groups with the possibility to create multiple interactions with complementary sites. Considering the relatively simple synthesis approach and other interesting properties (rigidity, aromatic character, H-bond formation) of squaramide motif, we combined this scaffold with different tacrine-based derivatives. In this study, we developed 21 novel dimers amalgamating squaric acid with either tacrine, 6-chlorotacrine or 7-methoxytacrine representing various AChEIs. All new derivatives were evaluated for their anti-cholinesterase activities, cytotoxicity using HepG2 cell line and screened to predict their ability to cross the blood-brain barrier. In this contribution, we also report in silico studies of the most potent AChE and BChE inhibitors in the active site of these enzymes., This project was conceived by JMC (IQOG, CSIC, Madrid, Spain), initially carried out experimentally by EM, in Madrid, thanks to a Short-Term Scientific Mission (from 30 January until the 28 April 2017) granted by EU COST Action (CA15135: “Multi-target paradigm for innovative ligand identification in the drug discovery process (MuTaLig)”), and continued in Hradec Kralove (Czech Republic) by EM in collaboration with BS, under the supervision of JK, who organized and planned all the biological analysis and wrote the manuscript. JMC is very thankful to EM, BS, and JK for their collaboration, and to the COST Action CA15135 for supporting this project. The study was supported by a grant of Ministry of Defence “Long Term Development Plan” Medical Aspects of Weapons of Mass Destruction of the Faculty of Military Health Sciences, University of Defence, by the Ministry of Education, Youth and Sports of Czech Republic (project ERDF no. CZ.02.1.01/0.0/0.0/18_069/0010054) and by MH CZ - DRO (University Hospital Hradec Kralove, No. 00179906). JMC thanks MINECO (Government of Spain) (SAF2015-65586-R) for support., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Synthesis, neuroprotective and antioxidant capacity of PBN-related indanonitrones

  • Jimenez-Almarza, Alicia
  • Diez-Iriepa, Daniel
  • Chioua, Mourad
  • Chamorro, Beatriz
  • Iriepa, Isabel
  • Martínez-Murillo, Ricardo
  • Hadjipavlou-Litina, Dimitra
  • Oset-Gasque, María Jesús
  • Marco-Contelles, José
In this work six PBN-related indanonitrones 1–6 have been designed, synthesized, and their neuroprotection capacity tested in vitro, under OGD conditions, in SH-SY5Y human neuroblastoma cell cultures. As a result, we have identified indanonitrones 1, 3 and 4 (EC50=6.64 ± 0.28 μM) as the most neuroprotective agents, and in particular, among them, indanonitrone 4 was also the most potent and balanced nitrone, showing antioxidant activity in three experiments [LOX (100 μM), APPH (51%), DPPH (36.5%)], being clearly more potent antioxidant agent than nitrone PBN. Consequently, we have identified (Z)-5-hydroxy-N-methyl-2,3-dihydro-1Hinden- 1-imine oxide (4) as a hit-molecule for further investigation., JMC thanks MINECO (Government of Spain) (SAF2015-65586-R), and UCJC for support [UCJC-2015-12 and UCJC-2018-04)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Synthesis, Monoamine Oxidase Inhibition and Computational Analysis of Diversely Substituted N-Propargylated-1,3,5-triazines

  • Chioua, Mourad
  • González-Camuñas, Arturo
  • Catarozzo, M. T.
  • Alcaro, S.
  • Ortuso, F.
  • Yáñez, Matilde
  • Marco-Contelles, José
In this work six diversely substituted N-propargylated-1,3,5-triazines have been designed, synthesized, and evaluated as monoamine oxidase (MAO) inhibitors. Very surprisingly, only 4,6-dichloro-N-(prop-2-yn-1-yl)-1,3,5-triazin-2-amine (1) showed modest, but selective MAO−B inhibition (IC=14.2 ± 0.7 μM), whose binding affinity has been investigated by computational analysis., JMC thanks MINECO (Government of Spain) (SAF2015-65586-R) for support. SA, FO and JMC thank the EU for support [COST Action “Multi-target paradigm for innovative ligand identification in the drug discovery process (MuTaLig)” (CA15137, Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Characterization of a cholesteroNitrone (ISQ-201), a novel drug candidate for the treatment of ischemic stroke

  • Martínez-Alonso, Emma
  • Escobar-Peso, Alejandro
  • Ayuso, María I.
  • Gonzalo-Gobernado, Rafael
  • Chioua, Mourad
  • Montoya, Juan J.
  • Montaner, Joan
  • Fernández, Israel
  • Marco-Contelles, José
  • Alcázar, Alberto
Nitrones have a well-recognized capacity as spin-traps and are considered powerful free radical scavengers, which are two important issues in hypoxia-induced oxidative stress and cell death in brain ischemia. Consequently, nitrones have been proposed as therapeutic agents in acute ischemic stroke (AIS). In this paper, we update the biological and pharmacological characterization of ISQ-201, a previously identified cholesteronitrone hybrid with antioxidant and neuroprotective activity. This study characterizes ISQ-201 as a neuroprotective agent against the hypoxia-induced ischemic injury. Transitory four-vessel occlusion and middle cerebral artery occlusion (tMCAO) were used to induce cerebral ischemia. Functional outcomes were determined using neurofunctional tests. Infarct area, neuronal death, and apoptosis induction were evaluated. In addition, ISQ-201 reactivity towards free radicals was studied in a theoretical model. ISQ-201 significantly decreased the ischemia-induced neuronal death and apoptosis, in a dose-dependent manner, showing its therapeutic effect when administered up until 6 h after post-ischemic reperfusion onset, effects that remained after 3 months from the ischemic episode. Furthermore, ISQ-201 significantly reduced infarct volume, leading to recovery of the motor function in the tMCAO model. Finally, the theoretical study confirmed the reactivity of ISQ-201 towards hydroxyl radicals. The results reported here prompted us to suggest ISQ-201 as a promising candidate for the treatment of AIS., This work was supported by the Instituto de Salud Carlos III and co-financed by the European Development Regional Fund (FEDER), grant number PI18/00255 and RETICS RD16/0019/0006 to A.A.; and by the Spanish Ministry of Economy and Competitiveness (MINECO), grant number SAF2015-65586-R, to J.M.C, and grant numbers CTQ2016-78205-P and CTQ2016-81797-REDC, to I.F., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Propargylamine-derived multi-target directed ligands for Alzheimer's disease therapy

  • do Carmo Carreiras, María
  • Ismaili, L.
  • Marco-Contelles, José
Current options for the treatment of Alzheimeŕs disease have been restricted to prescription of acetylcholinesterase inhibitors or N-methyl-D-aspartate receptor antagonist, memantine. Propargylamine-derived multi-target directed ligands, such as ladostigil, M30, ASS234 and contilisant, involve different pathways. Apart from acting as inhibitors of both cholinesterases and monoamine oxidases, they show improvement of cognitive impairment, antioxidant activities, enhancement of iron-chelating activities, protect against tau hyperphosphorylation, block metal-associated oxidative stress, regulate APP and Aβ expression processing by the non-amyloidogenic α-secretase pathway, suppress mitochondrial permeability transition pore opening, and coordinate protein kinase C signaling and Bcl-2 family proteins. Other hybrid propargylamine derivatives are also reported., JMC thanks friends and collaborators whose names are cited in the corresponding references, for the synthesis and pharmacological evaluation of some of the indoles disclosed here, as well as the CSIC, and Spanish (SAF2006-08764-C02-01SAF2009-07271; SAF2012-33304; SAF2015-65586-R) and EU [“Structure-based drug design for diagnosis and treatment of neurological diseases: dissecting and modulating complex function in the monoaminergic systems of the brain” (COST- 1103); “Multi-Target Paradigm for Innovative Ligand Identification in the Drug Discovery Process” (CA15135)] institutions for the generous financial support that made possible all these endeavors and ventures.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Recent Advances on Nitrones Design for Stroke Treatment

  • Marco-Contelles, José
The recent advances of tetramethylpyrazine nitrones and quinolylnitrones for the treatment of stroke have been reviewed and compared with other agents, showing promising therapeutic applications. As a result of a functional transformation of natural product ligustrazine, (Z)-N-tert-butyl-1-(3,5,6-trimethylpyrazin-2-yl)methanimine oxide (6) is a multitarget small nitrone showing potent thrombolytic activity and free radicals scavenging power, in addition to nontoxicity and blood-brain barrier permeability. Similarly, antioxidant (Z)-N-tert-butyl-1-(2-chloro-6-methoxyquinolin-3-yl)methanimine oxide (17) is a novel agent for cerebral ischemia therapy as it is able to scavenge different types of free radical species, showing strong neuroprotection and reduced infarct size., J.M.-C. thanks MINECO (Government of Spain, GrantSAF2015-65586-R), UCJC (Grants UCJC 2020-03 and UCJC2020-33), and ISCIII (Grant RD06/0026/1002) for support.J.M.-C. thanks Dr. Alcàzar (Department of Investigation,IRYCIS, Hospital Ramón y Cajal, Madrid, Spain), Prof. Oset-Gasque (Department of Biochemistry and Molecular Biology II,School of Pharmacy, UCM, Madrid, Spain), and Prof.Piotrowska (Faculty of Pharmacy, Medical University of Lodz,Poland) for continued collaboration. J.M.-C. also thanks theRENEVAS staff, in particular Pepe Castillo, Nacho Lizasoaìn,Marìa A. Moro, Antonio Dàvalos, and Joan Montaner, forstimulating and fruitful discussions. Figures 5−7 and Table 1 area reproduction of Figures 4, 7, 11, and Table 1, respectively, fromref66; Figures 9 and 10 are a reproduction of Figures 1 and 2,respectively, from ref65; Figure 12 is a reproduction of Figure 5from ref77, and for these reasons I thank the authors
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Synthesis, Neuroprotection, and Antioxidant Activity of 1,10-Biphenylnitrones as α-Phenyl-N-tert-butylnitrone Analogues in In Vitro Ischemia Models

  • Chamorro, Beatriz
  • Diez-Iriepa, Daniel
  • García-Vieira, David
  • Garagarza, Estíbaliz
  • Chioua, Mourad
  • Hadjipavlou-Litina, Dimitra
  • López-Muñoz, Francisco
  • Marco-Contelles, José
  • Oset-Gasque, María Jesús
Herein, we report the neuroprotective and antioxidant activity of 1,10-biphenyl nitrones (BPNs) 1–5 as -phenyl-N-tert-butylnitrone analogues prepared from commercially available [1,10- biphenyl]-4-carbaldehyde and [1,10-biphenyl]-4,40-dicarbaldehyde. The neuroprotection of BPNs 1-5 has been measured against oligomycin A/rotenone and in an oxygen–glucose deprivation in vitro ischemia model in human neuroblastoma SH-SY5Y cells. Our results indicate that BPNs 1–5 have better neuroprotective and antioxidant properties than -phenyl-N-tert-butylnitrone (PBN), and they are quite similar to N-acetyl-L-cysteine (NAC), which is a well-known antioxidant agent. Among the nitrones studied, homo-bis-nitrone BPHBN5, bearing two N-tert-Bu radicals at the nitrone motif, has the best neuroprotective capacity (EC50 = 13.16 1.65 and 25.5 3.93 M, against the reduction in metabolic activity induced by respiratory chain blockers and oxygen–glucose deprivation in an in vitro ischemia model, respectively) as well as anti-necrotic, anti-apoptotic, and antioxidant activities (EC50 = 11.2 3.94 M), which were measured by its capacity to reduce superoxide production in human neuroblastoma SH-SY5Y cell cultures, followed by mononitrone BPMN3, with one N-Bn radical, and BPMN2, with only one N-tert-Bu substituent. The antioxidant activity of BPNs 1-5 has also been analyzed for their capacity to scavenge hydroxyl free radicals (82% at 100 M), lipoxygenase inhibition, and the inhibition of lipid peroxidation (68% at 100 M). Results showed that although the number of nitrone groups improves the neuroprotection profile of these BPNs, the final effect is also dependent on the substitutent that is being incorporated. Thus, BPNs bearing N-tert-Bu and N-Bn groups show better neuroprotective and antioxidant properties than those substituted with Me. All these results led us to propose homo-bis-nitrone BPHBN5 as the most balanced and interesting nitrone based on its neuroprotective capacity in different neuronal models of oxidative stress and in vitro ischemia as well as its antioxidant activity. Keywords: antioxidants; 1,10-biphenyl nitrones; free radical scavengers; neuroprotection, This work was supported by grants from the Spanish Ministry of Economy and Competitiveness (SAF2015-65586-R) to JMC, and Camilo José Cela University (UCJC-2019-03) to JMC. DDI thanks the University of Alcalá and Spanish Ministry of Science, Innovation and Universities for pre-doctoral FPU grants. BC thanks the Spanish Ministry of Economy and Competitiveness for a contract supported by grant SAF2015-65586-R during 2019, and UCJC for a pre-doctoral grant starting 01/01/2020., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Privileged quinolylnitrones for the combined therapy of ischemic stroke and alzheimer’s disease

  • Alonso, José M.
  • Escobar-Peso, Alejandro
  • Palomino-Antolín, Alejandra
  • Diez-Iriepa, Daniel
  • Chioua, Mourad
  • Martínez-Alonso, E.
  • Iriepa, I.
  • Egea, Javier
  • Alcázar, Alberto
  • Marco-Contelles, José
Cerebrovascular diseases such as ischemic stroke are known to exacerbate dementia caused by neurodegenerative pathologies such as Alzheimer’s disease (AD). Besides, the increasing number of patients surviving stroke makes it necessary to treat the co-occurrence of these two diseases with a single and combined therapy. For the development of new dual therapeutic agents, eight hybrid quinolylnitrones have been designed and synthesized by the juxtaposition of selected pharmacophores from our most advanced lead-compounds for ischemic stroke and AD treatment. Biological analyses looking for efficient neuroprotective effects in suitable phenotypic assays led us to identify MC903 as a new small quinolylnitrone for the potential dual therapy of stroke and AD, showing strong neuroprotection on (i) primary cortical neurons under oxygen–glucose deprivation/normoglycemic reoxygenation as an experimental ischemia model; (ii), neuronal line cells treated with rotenone/oligomycin A, okadaic acid or β-amyloid peptide Aβ25–35, modeling toxic insults found among the effects of AD., This work was supported by the Instituto de Salud Carlos III and cofinanced by the Euro- pean Development Regional Fund (FEDER), grant number PI18/00255 and RETICS RD16/0019/0006, to A.A, Programa Miguel Servet CPII19/00005, PI19/00082 to JE, and by MINECO (Government of Spain) grant number SAF-2015-65586-R to J.M.-C. D.D.-I. thanks the Spanish Ministry of Science, Innovation and Universities for predoctoral FPU grant. A.E.-P. thanks Instituto de Salud Carlos III for the predoctoral contract IFI18/00011.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Use of Radical Oxygen Species Scavenger Nitrones to Treat Oxidative Stress-Mediated Hearing Loss: State of the Art and Challenges

  • Varela-Nieto, Isabel
  • Murillo-Cuesta, Silvia
  • Rodriguez-de la Rosa, Lourdes
  • Oset-Gasque, María Jesús
  • Marco-Contelles, José
Nitrones are potent antioxidant molecules able to reduce oxidative stress by trapping reactive oxygen and nitrogen species. The antioxidant potential of nitrones has been extensively tested in multiple models of human diseases. Sensorineural hearing loss has a heterogeneous etiology, genetic alterations, aging, toxins or exposure to noise can cause damage to hair cells at the organ of Corti, the hearing receptor. Noxious stimuli share a battery of common mechanisms by which they cause hair cell injury, including oxidative stress, the generation of free radicals and redox imbalance. Therefore, targeting oxidative stress-mediated hearing loss has been the subject of much attention. Here we review the chemistry of nitrones, the existing literature on their use as antioxidants and the general state of the art of antioxidant treatments for hearing loss., This work was supported by FEDER/B2017/BMD- 3688-MULTITARGET&VIEWCM and 0551-PSL-6-E NITROPROHEAR grants to IV-N, and SAF2015-65586-R, PDI-2019-105813RB-C21 grants to JM-C. SM-C and LR hold CIBERER (Institute of Health Carlos III) contracts co-financed with FEDER funds.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Synthesis of New Statin Derivatives

  • Chioua, Mourad
  • Marco-Contelles, José
Herein we report the synthesis of the new statin derivative MC609 in 80 % overall yield by sequential transformation of simvastatin including dehydration, and Michael addition of N-benzyl hydroxylamine followed by cyclization. The preparation of nitronestatins MC649 and MC645 is also described from (2S,4R)-4-((tert-butyldimethylsilyl)oxy)-6-oxotetrahydro-2H-pyran-2-carbaldehyde by reaction with N-benzyl hydroxylamine, and N-hydroxylamine followed by reduction with sodium cyanoborohydride and coupling with commercially available 2-chloro-6-methylquinoline-3-carbaldehyde, in 77 % and 24 % overall yield, respectively., This work was supported by grants from the Spanish Ministry of Economy and Competitiveness (grants SAF2012-33304, SAF2015-65586-R)
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Polyfunctionalized α-Phenyl-tert-butyl(benzyl)nitrones: Multifunctional Antioxidants for Stroke Treatment

  • Diez-Iriepa, Daniel
  • Knez, Damijan
  • Gobec, Stanislav
  • Iriepa, Isabel
  • de los Ríos, Cristóbal
  • Bravo, I.
  • López-Muñoz, Francisco
  • Marco-Contelles, José
  • Hadjipavlou-Litina, Dimitra
Nowadays, most stroke patients are treated exclusively with recombinant tissue plasminogen activator, a drug with serious side effects and limited therapeutic window. For this reason, and because of the known effects of oxidative stress on stroke, a more tolerable and efficient therapy for stroke is being sought that focuses on the control and scavenging of highly toxic reactive oxygen species by appropriate small molecules, such as nitrones with antioxidant properties. In this context, herein we report here the synthesis, antioxidant, and neuroprotective properties of twelve novel polyfunctionalized α-phenyl-tert-butyl(benzyl)nitrones. The antioxidant capacity of these nitrones was investigated by various assays, including the inhibition of lipid peroxidation induced by AAPH, hydroxyl radical scavenging assay, ABTS-decoloration assay, DPPH scavenging assay, and inhibition of soybean lipoxygenase. The inhibitory effect on monoamine oxidases and cholinesterases and inhibition of β-amyloid aggregation were also investigated. As a result, (Z)-N-benzyl-1-(2-(3-(piperidin-1-yl)propoxy)phenyl)methanimine oxide (5) was found to be one of the most potent antioxidants, with high ABTS scavenging activity (19%), and potent lipoxygenase inhibitory capacity (IC = 10 µM), selectively inhibiting butyrylcholinesterase (IC = 3.46 ± 0.27 µM), and exhibited neuroprotective profile against the neurotoxicant okadaic acid in a neuronal damage model. Overall, these results pave the way for the further in-depth analysis of the neuroprotection of nitrone 5 in in vitro and in vivo models of stroke and possibly other neurodegenerative diseases in which oxidative stress is identified as a critical player., This work was supported by grants from the Spanish Ministry of Economy and Competitiveness (SAF2015-65586-R) to JMC and Slovenian Research Agency ARRS (core program funding P1-0208). JMC thanks UCJC (Grants “OPTICOMC903” and “NACONT”) for the continued support. DDI thanks the Spanish Ministry of Science, Innovation, and Universities for the predoctoral FPU grant, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Synthesis and Antioxidant Properties of HeteroBisNitrones Derived from Benzene Dicarbaldehydes

  • Diez-Iriepa, Daniel
  • Iriepa, Isabel
  • López-Muñoz, Francisco
  • Marco-Contelles, José
  • Hadjipavlou-Litina, Dimitra
We report herein the synthesis and antioxidant profile of nine novel heterobisnitrones (hBNs) as new α-phenyl-tert-butylnitrone (PBN) analogues. The synthesized hBNs 1–9 were evaluated for their antioxidant activity using different in vitro techniques, while they were also tested as inhibitors of soybean LOX, as an indication of their anti-inflammatory effect. Nitrone hBN9 is the most potent antioxidant presenting higher anti-lipid peroxidation and hydroxyl radicals scavenging activities as well as higher lipoxygenase inhibition. In silico calculations reveal that hBN9 follows Lipinski’s rule of five and that the molecule is able to penetrate theoretically the brain. All these results led us to propose hBN9 as a new potent antioxidant nitrone., This work was supported by grants from the Spanish Ministry of Economy and Competitiveness (SAF2015-65586-R) to J.M.-C. J.M.-C. thanks to Universidad Camilo José Cela (Grants “OPTICOMC903” and “NACONT”) for continued support. D.D.-I. thanks to the Spanish Ministry of Science, Innovation and Universities for the predoctoral FPU grant.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Acetylcholinesterase Inhibition of Diversely Functionalized Quinolinones for Alzheimer's Disease Therapy

  • Bautista-Aguilera, Óscar M.
  • Ismaili, Lhassane
  • Chioua, Mourad
  • Andrys, R.
  • Schmidt, Monika
  • Bzonek, Petr
  • Martínez-Grau, Angeles
  • Beadle, C. D.
  • Vetman, T.
  • López-Muñoz, Francisco
  • Iriepa, Isabel
  • Refouvelet, Bernard
  • Musilek, Kamil
  • Marco-Contelles, José
In this communication, wereport the synthesis and cholinesterase (ChE)/monoamine oxidase (MAO) inhibition of 19 quinolinones (QN1-19) and 13 dihydroquinolinones (DQN1-13) designed as potential multitarget small molecules (MSM) for Alzheimer¿s disease therapy. Contrary to our expectations, none of them showed significant human recombinant MAO inhibition, but compounds QN8, QN9, and DQN7 displayed promising human recombinant acetylcholinesterase (hrAChE) and butyrylcholinesterase (hrBuChE) inhibition. In particular, molecule QN8 was found to be a potent and quite selective non-competitive inhibitor of hrAChE (IC50 = 0.29 M), with Ki value in nanomolar range (79 nM). Pertinent docking analysis confirmed this result, suggesting that this ligand is an interesting hit for further investigation., R.A., M.S., P.B., and K.M. were supported by European Regional Development Fund/European Social Fund (ERDF/ESF, project PharmaBrain, no. CZ.02.1.01/0.0/0.0/16_025/0007444), University of Hradec Kralove (no. SV2113-2019, VT2019-2021), and EU COST action CA15135 MuTaLig. J.M.C. thanks Ministerio de Economía (MINECO, SAF2015-65586-R) and Universidad Camilo José Cela (UCJC, grants UCJC 2020-03, and UCJC 2020-33) for support.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Nucleobase-Derived Nitrones: Synthesis and Antioxidant and Neuroprotective Activities in an In Vitro Model of Ischemia–Reperfusion

  • Chamorro, Beatriz
  • Glowacka, Iwona E.
  • Gotkowska, Joanna
  • Gulej, Rafał
  • Hadjipavlou-Litina, Dimitra
  • López-Muñoz, Francisco
  • Marco-Contelles, José
  • Piotrowska, Dorota G.
  • Oset-Gasque, María Jesús
Herein, we report the synthesis, antioxidant, and neuroprotective properties of some nucleobase-derived nitrones named 9a–i. The neuroprotective properties of nitrones, 9a–i, were measured against an oxygen-glucose-deprivation in vitro ischemia model using human neuroblastoma SH-SY5Y cells. Our results indicate that nitrones, 9a–i, have better neuroprotective and antioxidant properties than a-phenyl-N-tert-butylnitrone (PBN) and are similar to N-acetyl-Lcysteine (NAC), a well-known antioxidant and neuroprotective agent. The nitrones with the highest neuroprotective capacity were those containing purine nucleobases (nitrones 9f, g, B = adenine, theophylline), followed by nitrones with pyrimidine nucleobases with H or F substituents at the C5 position (nitrones 9a, c). All of these possess EC50 values in the range of 1–6 mM and maximal activities higher than 100%. However, the introduction of a methyl substituent (nitrone 9b, B = thymine) or hard halogen substituents such as Br and Cl (nitrones 9d, e, B = 5-Br and 5-Cl uracil, respectively) worsens the neuroprotective activity of the nitrone with uracil as the nucleobase (9a). The effects on overall metabolic cell capacity were confirmed by results on the high anti-necrotic (EC50′s » 2–4 mM) and antioxidant (EC50′s » 0.4–3.5 mM) activities of these compounds on superoxide radical production. In general, all tested nitrones were excellent inhibitors of superoxide radical production in cultured neuroblastoma cells, as well as potent hydroxyl radical scavengers that inhibit in vitro lipid peroxidation, particularly, 9c, f, g, presenting the highest lipoxygenase inhibitory activity among the tested nitrones. Finally, the introduction of two nitrone groups at 9a and 9d (bis-nitronas 9g, i) did not show better neuroprotective effects than their precursor mononitrones. These results led us to propose nitrones containing purine (9f, g) and pyrimidine (9a, c) nucleobases as potential therapeutic agents for the treatment of cerebral ischemia and/or neurodegenerative diseases, leading us to further investigate their effects using in vivo models of these pathologies., The synthetic part of the project was supported by the National Science Centre (synthesis of mononitrones—grant UMO-2013/11/N/NZ7/00723) and by the Medical University of Lodz internal funds (synthesis of bisnitrones—503/3-014-01/503-31-001) to D.G.P. J.M.-C. thanks MINECO (Government of Spain) (SAF2015-65586-R) and J.M-C. and M.J.O.-G. thanks UCJC (NitroStroke project, 2015-12 and NNTEE, 2020-03) for support.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Preclinical Characterization of Antioxidant Quinolyl Nitrone QN23 as a New Candidate for the Treatment of Ischemic Stroke

  • Martínez-Alonso, Emma
  • Escobar-Peso, Alejandro
  • Aliena-Valero, Alicia
  • Torregrosa, Germán
  • Chioua, Mourad
  • Fernández-Serra, Rocío
  • González-Nieto, Daniel
  • Ouahid, Youness
  • Salom, Juan B.
  • Masjuán, Jaime
  • Marco-Contelles, José
  • Alcázar, Alberto
Nitrones are encouraging drug candidates for the treatment of oxidative stress-driven diseases such as acute ischemic stroke (AIS). In a previous study, we found a promising quinolylnitrone, QN23, which exerted a neuroprotective effect in neuronal cell cultures subjected to oxygen–glucose deprivation and in experimental models of cerebral ischemia. In this paper, we update the biological and pharmacological characterization of QN23. We describe the suitability of intravenous administration of QN23 to induce neuroprotection in transitory four-vessel occlusion (4VO) and middle cerebral artery occlusion (tMCAO) experimental models of brain ischemia by assessing neuronal death, apoptosis induction, and infarct area, as well as neurofunctional outcomes. QN23 significantly decreased the neuronal death and apoptosis induced by the ischemic episode in a dose-dependent manner and showed a therapeutic effect when administered up to 3 h after post-ischemic reperfusion onset, effects that remained 11 weeks after the ischemic episode. In addition, QN23 significantly reduced infarct volume, thus recovering the motor function in a tMCAO model. Remarkably, we assessed the antioxidant activity of QN23 in vivo using dihydroethidium as a molecular probe for radical species. Finally, we describe QN23 pharmacokinetic parameters. All these results pointing to QN23 as an interesting and promising preclinical candidate for the treatment of AIS., This work was supported by the Instituto de Salud Carlos III and co-financed by the European Development Regional Fund (FEDER) through grants PI18/00255, RD16/0019/0006, and RD21/0006/0019 to J.M. and A.A., and RD16/0019/0008 and RD21/0006/0014 to J.B.S.; the MINECO grant SAF2015-65586-R to J.M.-C.; and the Comunidad de Madrid Neurocentro project B2017/BMD-3760 to D.G.-N.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Neuroprotective and antioxidant properties of new quinolylnitrones in in vitro and in vivo cerebral ischemia models

  • Chamorro, Beatriz
  • Izquierdo-Bermejo, Sara
  • Serrano, Julia
  • Hadjipavlou-Litina, Dimitra
  • Chioua, Mourad
  • López-Muñoz, Francisco
  • Marco-Contelles, José
  • Martínez-Murillo, Ricardo
  • Oset-Gasque, María Jesús
Cerebral ischemia is a condition affecting an increasing number of people worldwide, and the main cause of disability. Current research focuses on the search for neuroprotective drugs for its treatment, based on the molecular targets involved in the ischemic cascade. Nitrones are potent antioxidant molecules that can reduce oxidative stress. Here we report the neuroprotective properties and the antioxidant power of the six new quinolylnitrones (QNs) 1–6 for their potential application in stroke therapy. QNs 1–4 are 2-chloro-8-hydroxy-substituted QNs bearing N-t-butyl or N-benzyl substituents at the nitrone motif located at C3, whereas QN5 and QN6 are 8-hydroxy QNs bearing N-t-butyl or N-benzyl substituents at the nitrone motif located at C2, respectively. In vitro neuroprotection studies using QNs 1–6 in an oxygen-glucose-deprivation model of cerebral ischemia, in human neuroblastoma cell cultures, indicate that all QNs have promising neuroprotective, anti-necrotic, anti-apoptotic, and anti-oxidant properties against experimental ischemia–reperfusion in neuronal cultures. QN6 stands out as the most balanced nitrone out of all tested QNs, as it strongly prevents decreased neuronal metabolic activity (EC = 3.97 ± 0.78 μM), as well as necrotic (EC = 3.79 ± 0.83 μM) and apoptotic cell death (EC = 3.99 ± 0.21 μM). QN6 showed high capacity to decrease superoxide production (EC = 3.94 ± 0.76 μM), similar to its parent molecule α-phenyl-tert-butyl nitrone (PBN) and the well-known anti-oxidant molecule N-acetyl-l-cysteine (NAC). Thus, QN6 demonstrated the highest antioxidant power out of the other tested QNs. Finally, in vivo treatment with QN6 in an experimental permanent stroke model elicited a significant reduction (75.21 ± 5.31%) of the volume size of brain lesion. Overall, QN6 is a potential agent for the therapy of cerebral ischemia that should be further investigated., Dr. Hadjipavlou-Litina gratefully acknowledges Dr. A. Leo†, Μ. Μedlin and Biobyte Corp. 201 West 4th Street, Suite 204, Claremont, CA 91711, USA for free access to Bioloom program. Tis research was supported by grants from the Spanish Ministry of Economy and Competitiveness (SAF2015-65586-R) to J.M-C. and MJ.O-G. and J.M-C. thank Universidad Camilo José Cela (UCJC) (Grants “OPTICOMC903” and “NACONT”) for continued support. We thank Dr. J. Morón-Oset for helping to proofread the English style of this manuscript., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Neuroprotective and Antioxidant Properties of CholesteroNitrone ChN2 and QuinolylNitrone QN23 in an Experimental Model of Cerebral Ischemia: Involvement of Necrotic and Apoptotic Cell Death

  • Chamorro, Beatriz
  • Izquierdo-Bermejo, Sara
  • Martín de Saavedra, María Dolores
  • López-Muñoz, Francisco
  • Chioua, Mourad
  • Marco-Contelles, José
  • Oset-Gasque, María Jesús
Ischemic stroke is the leading cause of disability and the second leading cause of death worldwide. However, current therapeutic strategies are scarce and of limited efficacy. The abundance of information available on the molecular pathophysiology of ischemic stroke has sparked considerable interest in developing new neuroprotective agents that can target different events of the ischemic cascade and may be used in combination with existing treatments. In this regard, nitrones represent a very promising alternative due to their renowned antioxidant and anti-inflammatory effects. In this study, we aimed to further investigate the neuroprotective effects of two nitrones, cholesteronitrone 2 (ChN2) and quinolylnitrone 23 (QN23), which have previously shown great potential for the treatment of stroke. Using an experimental in vitro model of cerebral ischemia, we compared their anti-necrotic, anti-apoptotic, and antioxidant properties with those of three reference compounds. Both ChN2 and QN23 demonstrated significant neuroprotective effects (EC50 = 0.66 ± 0.23 μM and EC50 = 2.13 ± 0.47 μM, respectively) comparable to those of homo-bis-nitrone 6 (HBN6) and N-acetylcysteine (NAC) and superior to those of α-phenyl-N-tert-butylnitrone (PBN). While primarily derived from the nitrones’ anti-necrotic capacities, their anti-apoptotic effects at high concentrations and antioxidant powers—especially in the case of QN23—also contribute to their neuroprotective effects., This research was supported by grants from the Spanish Ministry of Economy and Competitiveness (SAF2015-65586-R) to J.M.-C., from Camilo José Cela University (UCJC) (Grants “MITOPI” and “NSNs”) to M.J.O.-G. and J.M.-C and from the Spanish Research Agency to M.D.M.S (PID2021-122723OA100)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

α-Phenyl-N-tert-Butylnitrone and Analogous α-Aryl-N-alkylnitrones as Neuroprotective Antioxidant Agents for Stroke

  • Marco-Contelles, José
© 2024 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)., The recent advances in research on the use of the antioxidant and neuroprotective agent α-phenyl-N-tert-butylnitrone (PBN) for the therapy of stroke have been reviewed. The protective effect of PBN in the transient occlusion of the middle cerebral artery (MCAO) has been demonstrated, although there have been significant differences in the neuronal salvaging effect between PBN-treated and untreated animals, each set of data having quite large inter-experimental variation. In the transient forebrain ischemia model of gerbil, PBN reduces the mortality after ischemia and the neuronal damage in the hippocampal cornu ammonis 1 (CA1) area of the hippocumpus caused by ischemia. However, PBN fails to prevent postischemic CA1 damage in the rat. As for focal cerebral ischemia, PBN significantly reduces cerebral infarction and decreases neurological deficit after ischemia using a rat model of persistent MCAO in rats. Similarly, the antioxidant and neuroprotective capacity of a number of PBN-derived nitrones prepared in the author’s laboratory have also been summarized here, showing their high potential therapeutic power to treat stroke., J.M.C. thanks Government of Spain (Grant SAF2015-65586-R), Universidad Camilo José Cela (UCJC 2020-03; UCJC 2020-33), and Instituto de Salud Carlos III (RD06/0026/1002) for support., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

In Vitro Modulation of Autophagy by New Antioxidant Nitrones as a Potential Therapeutic Approach for the Treatment of Ischemic Stroke

  • Izquierdo-Bermejo, Sara
  • Chamorro, Beatriz
  • Martín-de-Saavedra, María Dolores
  • Lobete, Miguel
  • López-Muñoz, Francisco
  • Marco-Contelles, José
  • Oset-Gasque, María Jesús
Stroke is a leading cause of death worldwide, yet current therapeutic strategies remain limited. Among the neuropathological events underlying this disease are multiple cell death signaling cascades, including autophagy. Recent interest has focused on developing agents that target molecules involved in autophagy to modulate this process under pathological conditions. This study aimed to analyze the role of autophagy in cell death induced by an in vitro ischemia–reperfusion (IR) model and to determine whether nitrones, known for their neuroprotective and antioxidant effects, could modulate this process. We focused on key proteins involved in different phases of autophagy: HIF-1α, BNIP3, and BECN1 for induction and nucleation, LC3 for elongation, and p62 for degradation. Our findings confirmed that the IR model promotes autophagy, initially via HIF-1α activation. Additionally, the neuroprotective effect of three of the selected synthetic nitrones (quinolylnitrones QN6 and QN23, and homo-bis-nitrone HBN6) partially derives from their antiautophagic properties, demonstrated by a downregulation of the expression of molecular markers involved in various phases of autophagy. In contrast, the neuroprotective power of cholesteronitrone ChN2 seems to derive from its promoting effects on the initial phases of autophagy, which could potentially help inhibit other forms of cell death. These results underscore the importance of autophagy modulation in neuroprotection, highlighting the potential of inhibiting prodeath autophagy and promoting prosurvival autophagy as promising therapeutic approaches in treating ischemic stroke clinically., This research was supported by grants from the Spanish Ministry of Economy and Com- petitiveness (SAF2015-65586-R) to J.M-C., from Camilo José Cela University (UCJC) (Grants “CHON- ICEN” and “NENS”) to M.J.O.-G. and J.M-C., and from the Spanish Research Agency to M.D.M.S, (PID2021-122723OA100)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Neuron-astrocyte signaling is preserved in the aging brain

  • Gómez-Gonzalo, Marta
  • Martin-Fernandez, Mario
  • Martínez-Murillo, Ricardo
  • Mederos, Sara
  • Hernández-Vivanco, Alicia
  • Jamison, Stephanie
  • Fernandez, Ana P.
  • Serrano, Julia
  • Calero, Pilar
  • Futch, Hunter S.
  • Corpas, Rubén
  • Sanfeliu, Coral
  • Perea, Gertrudis
  • Araque, Alfonso
Astrocytes play crucial roles in brain homeostasis and are emerging as regulatory elements of neuronal and synaptic physiology by responding to neurotransmitters with Ca2+ elevations and releasing gliotransmitters that activate neuronal receptors. Aging involves neuronal and astrocytic alterations, being considered risk factor for neurodegenerative diseases. Most evidence of the astrocyte-neuron signaling is derived from studies with young animals; however, the features of astrocyte-neuron signaling in adult and aging brain remain largely unknown. We have investigated the existence and properties of astrocyte-neuron signaling in physiologically and pathologically aging mouse hippocampal and cortical slices at different lifetime points (0.5 to 20 month-old animals). We found that astrocytes preserved their ability to express spontaneous and neurotransmitter-dependent intracellular Ca2+ signals from juvenile to aging brains. Likewise, resting levels of gliotransmission, assessed by neuronal NMDAR activation by glutamate released from astrocytes, were largely preserved with similar properties in all tested age groups, but DHPG-induced gliotransmission was reduced in aged mice. In contrast, gliotransmission was enhanced in the APP/PS1 mouse model of Alzheimer's disease, indicating a dysregulation of astrocyte-neuron signaling in pathological conditions. Disruption of the astrocytic IP3 R2 mediated-signaling, which is required for neurotransmitter-induced astrocyte Ca2+ signals and gliotransmission, boosted the progression of amyloid plaque deposits and synaptic plasticity impairments in APP/PS1 mice at early stages of the disease. Therefore, astrocyte-neuron interaction is a fundamental signaling, largely conserved in the adult and aging brain of healthy animals, but it is altered in Alzheimer's disease, suggesting that dysfunctions of astrocyte Ca2+ physiology may contribute to this neurodegenerative disease. GLIA 2017 GLIA 2017;65:569-580., Grant sponsor: Research Grant; Grant number: R01NS097312-01; Grant sponsor: NIH-NINDS; Grant numbers: R01NS097312-01 We thank W. Buño for helpful comments; B. Pro, S. Fernández and M. Palancar for technical assistance; Dr. J. Chen (UCSD, USA) for providing IP3R2−/− mice. Work supported by MINECO: SAF2015-65586 to RM; SAF2012-39852-C02-02 to CS; BFU2013-47265-R, BFU2016-75107-P, and RYC-2012-12014 to GP; CSD2010-00045 to CS, GP and AA; Cajal Blue Brain, Human Frontier Science Program and R01NS097312-01 to A.A., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The proof-of-concept of ASS234: Peripherally administered ASS234 enters the central nervous system and reduces pathology in a male mouse model of Alzheimer disease

  • Serrano, Mari Paz
  • Herrero-Labrador, Raquel
  • Futch, Hunter S.
  • Serrano, Julia
  • Romero, Alejandro
  • Fernández Fernández, Ana Patricia
  • Samadi, Abdelouahid
  • Unzeta, Mercedes
  • Marco-Contelles, José
  • Martínez-Murillo, Ricardo
The heterogeneity of Alzheimer disease requires the development of multitarget drugs for treating the symptoms of the disease and its progression. Both cholinergic and monoamine oxidase dysfunctions are involved in the pathological process. Thus, we hypothesized that the development of therapies focused on these targets might be effective. We have developed and assessed a new product, coded ASS234, a multipotent acetyl and butyrylcholinesterase/monoamine oxidase A-B inhibitor with a potent inhibitory effect on amyloid-β aggregation as well as antioxidant and antiapoptotic properties. But there is a need to reliably correlate in vitro and in vivo drug release data., The study received research support from the MINECO (Government of Spain grant SAF2015-65586 awarded to R. Martínez-Murillo and J. Marco-Contelles and grant SAF2012-33304 awarded to J. Marco-Contelles). The authors thank Universidad Camilo José Cela for support (grant 2014-35)., Peer reviewed
Docta Complutense
Publicación Artículo científico (JournalArticle)

The proof-of-concept of ASS234: Peripherally administered ASS234 enters the central nervous system and reduces pathology in a male mouse model of Alzheimer disease

  • Serrano Regal, María Paz
  • Herrero Labrador, Raquel
  • Futch, Hunter S.
  • Serrano, Julia
  • Romero Martínez, Manuel Alejandro
  • Fernandez, Ana Patricia
  • Samadi, Abdelouahid
  • Unzeta, Mercedes
  • Marco Contelles, José Luis
  • Martínez Murillo, Ricardo
Background: The heterogeneity of Alzheimer disease requires the development of multitarget drugs for treating the symptoms of the disease and its progression. Both cholinergic and monoamine oxidase dysfunctions are involved in the pathological process. Thus, we hypothesized that the development of therapies focused on these targets might be effective. We have developed and assessed a new product, coded ASS234, a multipotent acetyl and butyrylcholinesterase/monoamine oxidase A–B inhibitor with a potent inhibitory effect on amyloid-β aggregation as well as antioxidant and antiapoptotic properties. But there is a need to reliably correlate in vitro and in vivo drug release data. Methods: We examined the effect of ASS234 on cognition in healthy adult C57BL/6J mice in a model of scopolamine-induced cognitive impairment that often accompanies normal and pathological aging. Also, in a characterized transgenic APPswe/PS1ΔE9 mouse model of Alzheimer disease, we examined the effects of short-term ASS234 treatment on plaque deposition and gliosis using immunohistochemistry. Toxicology of ASS234 was assessed using a quantitative high-throughput in vitro cytotoxicity screening assay following the MTT assay method in HepG2 liver cells. Results: In vivo, ASS234 significantly decreased scopolamine-induced learning deficits in C57BL/6J mice. Also, reduction of amyloid plaque burden and gliosis in the cortex and hippocampus was assessed. In vitro, ASS234 exhibited lesser toxicity than donepezil and tacrine. Limitations: The study was conducted in male mice only. Although the Alzheimer disease model does not recapitulate all features of the human disease, it exhibits progressive monoaminergic neurodegeneration. Conclusion: ASS234 is a promising alternative drug of choice to treat the cognitive decline and neurodegeneration underlying Alzheimer disease.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Multi-Target Directed Donepezil-Like Ligands for Alzheimer's Disease

  • Unzeta López, Mercedes|||0000-0002-7113-3383
  • Esteban, Gerard|||0000-0002-9383-2150
  • Bolea Tomás, Irene|||0000-0001-9591-980X
  • Fogel, Wieslawa A.
  • Ramsay, Rona R.
  • Youdim, Moussa B. H.
  • Tipton, Keith F.
  • Marco-Contelles, José
HIGHLIGHTS Alzheimer's disease (AD), the most common form of adult onset dementia, is an age-related neurodegenerative disorder characterized by progressive memory loss, decline in language skills, and other cognitive impairments. Although its etiology is not completely known, several factors including deficits of acetylcholine, β-amyloid deposits, τ-protein phosphorylation, oxidative stress, and neuroinflammation are considered to play significant roles in the pathophysiology of this disease. For a long time, AD patients have been treated with acetylcholinesterase inhibitors such as donepezil (Aricept®) but with limited therapeutic success. This might be due to the complex multifactorial nature of AD, a fact that has prompted the design of new Multi-Target-Directed Ligands (MTDL) based on the "one molecule, multiple targets" paradigm. Thus, in this context, different series of novel multifunctional molecules with antioxidant, anti-amyloid, anti-inflammatory, and metal-chelating properties able to interact with multiple enzymes of therapeutic interest in AD pathology including acetylcholinesterase, butyrylcholinesterase, and monoamine oxidases A and B have been designed and assessed biologically. This review describes the multiple targets, the design rationale and an in-house MTDL library, bearing the N -benzylpiperidine motif present in donepezil, linked to different heterocyclic ring systems (indole, pyridine, or 8-hydroxyquinoline) with special emphasis on compound ASS234, an N -propargylindole derivative. The description of the in vitro biological properties of the compounds and discussion of the corresponding structure-activity-relationships allows us to highlight new issues for the identification of more efficient MTDL for use in AD therapy.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

ASS234, As a New Multi-Target Directed Propargylamine for Alzheimer's Disease Therapy

  • Marco-Contelles, José
  • Unzeta López, Mercedes|||0000-0002-7113-3383
  • Bolea Tomás, Irene|||0000-0001-9591-980X
  • Esteban, Gerard|||0000-0002-9383-2150
  • Ramsay, Rona R.
  • Romero, Alejandro|||0000-0001-5483-4973
  • Martínez-Murillo, Ricard
  • Carreiras, M. Carmo
  • Ismaili, Lhassane
Highlights: The complex nature of Alzheimer's disease (AD) has prompted the design of Multi-Target-Directed Ligands (MTDL) able to bind to diverse biochemical targets involved in the progress and development of the disease. In this context, we have designed a number of MTD propargylamines (MTDP) showing antioxidant, anti-beta-amyloid, anti-inflammatory, as well as cholinesterase and monoamine oxidase (MAO) inhibition capacities. Here, we describe these properties in the MTDL ASS234, our lead-compound ready to enter in pre-clinical studies for AD, as a new multipotent, permeable cholinesterase/monoamine oxidase inhibitor, able to inhibit Aβ-aggregation, and possessing antioxidant and neuroprotective properties.